CHINOOK THERAPEUTICS INC (KDNY) Stock Price, Quote, News and Overview
NASDAQ:KDNY - Nasdaq - US16961L1061 - Common Stock - Currency: USD
KDNY Quote, Performance and Key Statistics
40.39
+0.09 (+0.22%)
The current stock price of KDNY is 40.39 USD. In the past month the price increased by 2.98%. In the past year, price increased by 95.69%.
KDNY Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.97 | 357.10B | ||
| AMGN | AMGEN INC | 15.29 | 162.72B | ||
| GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
| NTRA | NATERA INC | N/A | 21.43B | ||
| BIIB | BIOGEN INC | 8.54 | 20.49B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Related stock screener links
About KDNY
Company Profile
Chinook Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering, developing, and commercializing precision medicines for rare, severe chronic kidney diseases. The company is headquartered in Seattle, Washington and currently employs 214 full-time employees. The company went IPO on 2015-04-15. The firm is focused on discovering, developing and commercializing precision medicines for kidney diseases. Its lead product candidate is atrasentan, a potent and selective endothelin A receptor (ET A receptor), antagonist that is developing for the treatment of proteinuric glomerular diseases. Atrasentan is in Phase III trials for the treatment of IgA nephropathy (IgAN) and proteinuric glomerular diseases. Its second product candidate, BION-1301, is an anti-APRIL monoclonal antibody also in Phase II development for patients with IgAN. Its third product candidate, CHK-336, is an oral small molecule lactate dehydrogenase (LDHA), inhibitor for the treatment of primary and idiopathic hyperoxaluria that is in a Phase I clinical trial in healthy volunteers. In addition, the Company is also conducting research programs in several other rare, severe chronic kidney diseases.
Company Info
CHINOOK THERAPEUTICS INC
400 Fairview Avenue North, Suite 900
Seattle WASHINGTON 98102 US
CEO: Eric L. Dobmeier
Employees: 214
Company Website: https://www.chinooktx.com/
Phone: 12064857051.0
CHINOOK THERAPEUTICS INC / KDNY FAQ
What is the stock price of CHINOOK THERAPEUTICS INC today?
The current stock price of KDNY is 40.39 USD. The price increased by 0.22% in the last trading session.
What is the ticker symbol for CHINOOK THERAPEUTICS INC stock?
The exchange symbol of CHINOOK THERAPEUTICS INC is KDNY and it is listed on the Nasdaq exchange.
On which exchange is KDNY stock listed?
KDNY stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for CHINOOK THERAPEUTICS INC stock?
17 analysts have analysed KDNY and the average price target is 41.11 USD. This implies a price increase of 1.77% is expected in the next year compared to the current price of 40.39. Check the CHINOOK THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is CHINOOK THERAPEUTICS INC worth?
CHINOOK THERAPEUTICS INC (KDNY) has a market capitalization of 2.90B USD. This makes KDNY a Mid Cap stock.
How many employees does CHINOOK THERAPEUTICS INC have?
CHINOOK THERAPEUTICS INC (KDNY) currently has 214 employees.
What are the support and resistance levels for CHINOOK THERAPEUTICS INC (KDNY) stock?
CHINOOK THERAPEUTICS INC (KDNY) has a support level at 38.89 and a resistance level at 40.4. Check the full technical report for a detailed analysis of KDNY support and resistance levels.
Is CHINOOK THERAPEUTICS INC (KDNY) expected to grow?
The Revenue of CHINOOK THERAPEUTICS INC (KDNY) is expected to decline by -50.48% in the next year. Check the estimates tab for more information on the KDNY EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy CHINOOK THERAPEUTICS INC (KDNY) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of KDNY, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of KDNY, evaluating the profitability, health, valuation and growth aspects
- CHINOOK THERAPEUTICS INC (KDNY) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- CHINOOK THERAPEUTICS INC (KDNY) Sales and EPS estimates to see what analysts future expectations are.
- CHINOOK THERAPEUTICS INC (KDNY) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- CHINOOK THERAPEUTICS INC (KDNY) Insider and Institutional Ownership to learn about the owners and their transactions.
- CHINOOK THERAPEUTICS INC (KDNY) Stock Chart to make your own analysis
- CHINOOK THERAPEUTICS INC (KDNY) Latest news and press-releases to stay up to date.
Does CHINOOK THERAPEUTICS INC (KDNY) stock pay dividends?
KDNY does not pay a dividend.
When does CHINOOK THERAPEUTICS INC (KDNY) report earnings?
CHINOOK THERAPEUTICS INC (KDNY) will report earnings on 2023-11-08, after the market close.
What is the Price/Earnings (PE) ratio of CHINOOK THERAPEUTICS INC (KDNY)?
CHINOOK THERAPEUTICS INC (KDNY) does not have a PE ratio as the earnings reported over the last twelve months were negative (-3.52).
KDNY Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to KDNY. When comparing the yearly performance of all stocks, KDNY is one of the better performing stocks in the market, outperforming 98.56% of all stocks.
KDNY Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to KDNY. No worries on liquidiy or solvency for KDNY as it has an excellent financial health rating, but there are worries on the profitability.
KDNY Financial Highlights
Over the last trailing twelve months KDNY reported a non-GAAP Earnings per Share(EPS) of -3.52. The EPS decreased by -107.06% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | 0 |
KDNY Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 73% to KDNY. The Buy consensus is the average rating of analysts ratings from 17 analysts.
For the next year, analysts expect an EPS growth of -13.68% and a revenue growth -50.48% for KDNY